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Abstract
Background: The aim of the present study was to analyse the expression of Secreted protein acidic and rich in
cysteine (SPARC) in nasopharyngeal carcinoma (NPC) specimens, and to evaluate its correlation with
clinicopathologic features, including survival of patients with NPC
Methods: NPC tissue microarrays (TMAs) were constructed from Sun Yat-sen University Cancer Center (SYSUCC),
another three centers on mainland China, Singapore and Hong Kong. Using quantitative RT-PCR and Western-
blotting techniques, we detected mRNA and protein expression of SPARC in NPC cell lines and immortalized
nasopharyngeal epithelial cells (NPECs) induced by Bmi-1 (NPEC2 Bmi-1). The difference of SPARC expression in the
cell lines was tested using a t-test method. The relationship between the SPARC expression and clinicopathological
data was assessed by chi-square. Survival analysis was estimated using the Kaplan-Meier approach with log-rank
test. Univariate and multivariate analyses of clinical variables were performed using Cox proportional hazards
regression models.
Results: The expression levels of SPARC mRNA and protein were markedly higher in NPC cell lines than in NPEC2
Bmi-1. Especially, the expression levels of SPARC mRNA and protein were much lower in the 6-10B than in the 5-8
F( P = 0.002, P = 0.001). SPARC immunostaining revealed cytoplasmic localization in NPC cells and no staining in
the stroma and epithelium.
In addition, high level of SPARC positively correlated with the status of distant metastasis (P = 0.001) and WHO
histological classification (P = 0.023). NPC patients with high SPARC expression also had a significantly poorer
prognosis than patients with low SPARC expression (log-rank test, P < 0.001), especially patients with advanced
stage disease (log-rank, P < 0.001). Multivariate analysis suggested that the level of SPARC expression was an
independent prognostic indicator for the overall survival of patients with NPC (P < 0.001).
Conclusions: SPARC expression is common in NPC patients. Our data shows that elevated SPARC expression is a
potential unfavorable prognostic factor for patients with NPC.
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Nasopharyngeal carcinoma (NPC) is unique amongst
head and neck cancers because of its peculiar epidemio-
logical and biological characteristics. NPC is a rare
tumor in most parts of the world, but it occurs at a
high rate in Southeast Asia. Unlike other head and neck
malignancies, NPC is notorious for its highly metastatic
nature [1]. Metastasis to regional lymph nodes or distant
organs, and local recurrence, are two major causes for
treatment failure of this cancer. Although NPC is classi-
fied as a subtype of head and neck squamous cell carci-
noma, its unique epidemiology, clinical characteristics,
etiology, and histopathology warrant separate efforts for
the study of its underlying molecular mechanisms of
carcinogenesis [2]. For example, NPC patients tend to
present at a more advanced stage of disease because the
primary anatomical site of tumor growth is located in a
silent area, and they exhibit higher metastatic potential
when compared to other head and neck squamous cell
carcinoma [3-5].
Currently, the prediction of NPC prognosis is mainly
based on clinical (Tumor, Node, Metastasis) TNM sta-
ging. However, NPC patients with the same clinical
stage often present different clinical outcomes, suggest-
ing that TNM staging is insufficient for precisely pre-
dicting the prognosis of this disease [6-9]. The specific
genetic changes underlying the development and pro-
gression of this neoplasm are not completely under-
stood. Therefore, the identification of useful biomarkers
associated with NPC holds the promise of improved
clinical management.
Secreted protein acidic and rich in cysteine (SPARC),
also known as osteonectin or BM-40, is a matricellular
glycoprotein that functions primarily to promote extra-
cellular matrix deposition [10]. It is expressed at high
levels in bone tissues and is widely distributed in many
other tissues and cell types [11]. Originally detected as a
component of bone, it is now known to be expressed at
high levels in tissues undergoing mineralization, prolif-
eration, and re-modeling, as well as in a wide range of
malignancies [12].
High SPARC expression in primary tumors, including
gastric cancer, correlates with metastasis and poor prog-
nosis [13,14]. Elevated mRNA level in tumor tissue is
associated with a poorer survival in breast cancer
[15-17], osteosarcoma [18], glioblastoma [19], oesopha-
geal carcinoma [20], and bladder cancer [21]. Immuno-
histochemical detection of SPARC protein in tumor
cells is associated with survival in meningiomas [22],
tongue carcinoma [23], head and neck cancer [24] and
cutaneous malignant melanomas [25]. Interestingly, in
pancreatic adenocarcinoma [26,27] and non-small cell
lung cancer [28], only SPARC expression in peritu-
moural stroma is associated with survival. The possible
clinical significance of SPARC expression has remained
unclear in NPC patients.
In this study, we first investigated the clinical variables
of SPARC expression in NPC patients from different
institutions. Using quantitative RT-PCR and Western
blot analysis, we detected mRNA and protein expression
of SPARC in NPC cell lines, and immortalized naso-
pharyngeal epithelial cells (NPECs) induced by Bmi-1
(NPEC2 Bmi-1). Immunohistochemistry (IHC) on
TMAs was used to assess SPARC expression in NPC tis-
sue from three cities in mainland China, as well as Hong
Kong and Singapore. Then, the relationship between
S P A R Ce x p r e s s i o na n dN P Cp a t i e n t s ’ prognosis was
investigated. Overall, our findings indicate that high
S P A R Ce x p r e s s i o nm a ys e r v ea sa ni n d e p e n d e n tp r o g -
nostic marker for predicting poor prognosis in NPC
patients, especially those with advanced stage disease.
Methods
Samples and cases
For this retrospective study, enrolled NPC cases
included a cohort of 836 patients with incident, primary,
biopsy-confirmed NPC who were diagnosed between
1992 and 2002 at SYSUCC (Guangzhou, China); a
cohort of 132 patients with incident, primary, biopsy-
confirmed NPC who were diagnosed between 1992 and
2004 from three other cities in mainland China; and a
cohort of 125 patients with biopsy-confirmed NPC who
were diagnosed between 2002 and 2004 at cancer cen-
ters in Hong Kong and Singapore. The clinicopathologi-
cal characteristics are summarized in Table 1. Inclusion
criteria were: availability of hematoxylin and eosin
(H&E) slides with invasive tumor components, treat-
ment before the end of 2005, availability of follow-up
data, no history of treated cancer, and appropriate
patient informed consent. Cancer TNM stage was
defined according to the 1992 China Staging system for
cases from mainland China (n = 968), and the 1997
American Joint Committee on Cancer staging system
[29,30] for cases from Hong Kong and Singapore (n =
125). All patients underwent standard curative radio-
therapy with or without chemotherapy. Institute
Research Medical Ethics Committee of SYSUCC granted
approval for this study.
Tissue microarrays (TMAs) construction
A fresh section stained with hematoxylin and eosin (HE)
was cut from each block. Individual donor blocks were
overlaid with the corresponding HE slides, and areas for
TMA sampling were marked. Using instrumentation
developed at the Mayo Clinic (Beech Instrument Co.,
USA), two cylindrical cores of 1.0 mm at their greatest
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block and transferred to pre-molded recipient paraffin
blocks at defined array positions. Recipient paraffin
blocks contained holes of appropriate dimension in a
grid pattern of a maximum of 11 holes in width by 14
holes in length, allowing for 154 tissue cores per block.
This design permitted multiple blocks with identical
array patterns to be constructed simultaneously, serially
sectioned at 4 μm onto “charged” glass slides, and stored
at 4°C.
Immunohistochemistry staining
Immunohistochemistry (IHC) staining was performed
using TMA sections that were rehydrated through a
graded alcohol series. Endogenous peroxidase activity
was blocked with 3% hydrogen peroxide for 10 min at
room temperature. For antigen retrieval, TMA slides
were boiled in tris (hydroxymethyl) aminomethane-ethy-
lenediaminetetraacetic acid buffer (pH 8.0) in a pressure
cooker for 2 min, 30 sec. TMA slides were incubated
with anti-SPARC (1:100 dilution; Abnova Laboratories,
U S A ) ,i nam o i s tc h a m b e ro v e r n i g h ta t4 ° C .T h en e x t
day, slides were treated by HRP polymer conjugated
anti-mouse secondary antibody (Dako, Glostrup, Den-
mark) for 30 min at 37°C, followed by a 3 min incuba-
tion in diaminobenzidine (DAB) solution for protein
detection. The nucleus was counterstained with Meyer’s
hematoxylin. A negative control was obtained by repla-
cing the primary antibody with normal murine IgG.
Assessment of immunostaining
Immunostaining results were evaluated and scored inde-
pendently by two pathologists lacking knowledge of the
clinicopathological outcomes of the patients. SPARC stain-
ing results were scored as four levels according to the per-
centage of cytoplasmic positive tumor cells in 10 high
power fields as follows [31]. (-): less than 5%; (+): 6%-25%;
(++): 26-50%; (+++): more than 50%. Likewise, staining
intensity was assigned a score as follows: 0 = no staining;
1 = weak staining; 2 = moderate staining; 3 = strong stain-
ing. The two individual parameters were added [32],
resulting in an immunoreactivity score (IRS) ranging from
0 to 6. We defined cases with IRS > 4 as high expression,
and cases with IRS ≤ 4 as low expression [32].
Cell lines and cell cultures
Immortalized NPECs induced by Bmi-1 (NPEC2 Bmi-1)
were established as described previously [33] and grown
in keratinocyte/serum-free medium (Invitrogen). The
human NPC cell lines CNE1, CNE2, HONE1, SUNE1,
5-8 F, and 6-10B were incubated in RPMI-1640 medium
supplemented with 10% fetal bovine serum (FBS)
(Gibco, USA), 100 units of penicillin/ml and 100 μgo f
streptomycin/ml. The human NPC cell line C666 was
cultured in RPMI 1640 medium (Gibco, USA) contain-
ing 15% FBS. All cell lines were maintained in a humidi-
fied incubator at 37°C with 5% CO2.
RNA extraction and quantitative RT-PCR analysis of
SPARC
Total RNA from 7 NPC cell lines and NPEC2 Bmi-1
were isolated using Trizol reagent ((Life Technologies,
Grand Island, NY) according to the manufacturer’s
instructions. RNA concentrations were determined with
NanoDrop (NanoDrop Technologies, Inc.). Following the
Table 1 Clinicopathological characteristics and follow-up
data of 1093 NPC patients
Characteristic Number of patients
(%)
Sex
Female 318 (29.1)
Male 775 (70.9)
Age (years)
Median
(range) 47 (15-90)
≤ 47 568
> 47 517
Missing 8
Follow-up time (months)
Median 67 (1-120)
(range)
Clinical stage
I-II 315 (29.0)
III-IV 773 (71.0)
Missing 5
Relapse
No 1001 (91.7)
Yes 91 (8.3)
Missing 1
Metastasis
No 984 (90.1)
Yes 108 (9.9)
Missing 1
Therapeutic modality
Radiotherapy 766 (70.6)
Chemotherapy 10 (0.9)
Radiochemotherapy 309 (28.5)
Missing 8
WHO histological classification
NKUC 853 (78.3)
NKDC 206 (18.9)
KSCC 30 (2.8)
Missing 4
OS rate (%)
5-year 69.1
Abbreviations: NPC nasopharyngeal carcinoma; WHO World Health
Organization; NKUC non-keratinizing undifferentiated carcinoma; NKDC non-
keratinizing differentiated carcinoma; KSCC keratinizing squamous cell
carcinoma; OS overall survival
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ug total RNA by TaKaRa reagent and amplified using
SYBR Green chemistry (Invitrogen) on an ABI 7500HT
instrument (ABI Inc., USA). The following primers were
used: SPARC forward 5’-GTGCAGAGGAAACCGAA-
GAG-3’;SPARC reverse 5’-TCATTGCTGCACACCTT
CTC-3’;G A P D Hf o r w a r d5 ’-CTGCACCACCAACTGC
TTAG-3’;GAPDH reverse 5’AGGTCCACCACTGA-
CACGTT-3’. After 40 cycles, data reduction was per-
formed with Sequence Detection System Software
(Applied Biosystems Inc.,). For data analysis, threshold
cycles (Ct) for GAPDH (reference) and SPARC (sample)
were determined in triplicates (shown as arithmetical
mean). The quantity of SPARC in each NPC cell line
relative to the average expression in NPEC2 Bmi-1 cell
line, was calculated using the equation: RQ = 2-
ΔΔCT
[34].
Western blotting analysis
Equal amounts of whole-cell lysates were resolved by
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) and transferred to a polyvinylidene
difluoride (PVDF) membrane (Pall Corp., Port Washing-
ton, NY). This was followed by incubation with primary
mouse monoclonal antibodies against human SPARC
(1:100 dilution; Abnova), and mouse monoclonal antibo-
dies against human GAPDH (1:4000 dilution; Santa
Cruz Biotechnology, Santa Cruz, CA), respectively.
Immunoreactive proteins were detected with enhanced
chemiluminescencedetection reagents (Amersham Bios-
ciences, Uppsala, Sweden) according to the manufac-
turer’s instructions.
Statistical analysis
Data was analyzed using SPSS software, version 16.0 (SPSS
I n c . ,C h i c a g o ,U S A ) .T h ed i f f e r e n c eo fm e a n s( S P A R C
expression in the NPEC2 Bmi-1 and NPC cell lines) was
tested using a t-test method. The correlation between
SPARC expression and clinicopathological parameters was
assessed by chi-square test. Kaplan-Meier analysis and log-
rank test were used to assess survival rate, and to compare
survival rate differences. Univariate and multivariate
regression analysis were performed with the Cox propor-
tional hazards regression model to analyse the factors
related to prognosis. A P-value less than 0.05 was consid-
ered as statistically significant.
Results
SPARC expression in NPC cell lines and tissue
We first evaluated the endogenous expression of SPARC
in several human NPC cell lines and NPEC2 Bmi-1 cell
line. To determine SPARC expression, quantitative real-
time PCR was performed to evaluate SPARC mRNA
expression levels in NPC cell lines including CNE1, CNE2,
HONE1, SUNE1 and C666, and an immortalized primary
nasopharyngeal epithelial cell line, NPEC2 Bmi-1. Com-
pared to NPEC2 Bmi-1 cells, high expression levels of
SPARC mRNA were observed in the NPC cell lines CNE1,
CNE2, HONE1, SUNE1 and C666 (Figure 1A). Western
blot analysis also revealed over-expression of SPARC pro-
tein in CNE1, CNE2, HONE1, SUNE1 and C666, com-
pared to NPEC2 Bmi-1 (Figure 1B). Moreover, the
expression of SPARC in the cell lines 5-8 F (a NPC cell
line with high tumorigenic and metastatic ability) and 6-
10B (a NPC cell line with high tumorigenic and low meta-
static ability) were also analysed. Figure 1C-D showed that
the expression levels of SPARC mRNA and protein in the
6-10B were lower than in the 5-8 F. The significance was
assessed by t-test (P = 0.002, P = 0.001). The expression of
SPARC protein was determined by IHC in NPC tissues.
No staining was found in the stroma and the normal naso-
pharyngeal epithelial of NPC tissue (Figure 2A-B). Repre-
sentative staining of SPARC was shown in Figure 2C-2J.
SPARC immunostaining revealed cytoplasmic localization
in NPC cells.
SPARC expression and overall survival
In the all NPC patients (1093 cases), the 5-year overall
survival (OS) rate was 69.1% (Figure 3A). We defined
701 patients (64.1%) as low expression and 392 patients
(35.9%) as high expression according to levels of SPARC
expression. Among all 1093 patients, the 5-year OS
rates differed substantially and statistically significantly
between low expression and high expression patients
(74.9% vs. 58.9%, Figure 3B; P < 0.001). After stratifica-
tion by clinical stage, SPARC expression remained a sig-
nificant predictor of NPC prognosis in the advanced
stage (stages III-IV) but not a significant predictor in
the early stage (stages I-II). In the early stage, the 5-year
OS rate was 93.7% among low-expression patients, and
88.8% among high-expression patients (Figure 3C; P =
0.256). In addition, in the advanced stage, the 5-year OS
rate was 66.8% among low-expression patients, and
48.8% among high-expression patients (Figure 3D; P <
0.001). The expression of SPARC also remained a clini-
cal and statistical predictor of prognosis after stratifica-
tion by WHO classification (P <0 . 0 0 1 ) ,r e l a p s e( P <
0.001) and metastasis (P < 0.001) (data not shown).
Association of SPARC with NPC patient’s
clinicopathological parameters and Cox Proportional
Hazards Survival Analysis
The high or low expression rates of SPARC in NPC
with respect to several standard clinicopathological fea-
tures are presented in Table 2. There was a significant
association between SPARC expression and distant
metastasis of NPC (P = 0.001, Table 2), and WHO clas-
sification (P = 0.023, Table 2). There was no significant
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copathological parameters, such as age, sex, clinical
s t a g ea n dr e l a p s e( P > 0.05, Table 2). Univariate Cox
proportional hazard regression analysis revealed that
high SPARC expression was the most significant predic-
tive factor for poor prognosis of patients with NPC (P <
0.001, Hazard ration [HR] = 1.785). Other clinicopatho-
logical parameters, including age (P < 0.001, HR =
1.554), sex (P = 0.039, HR = 0.78), and clinical stage
(P < 0.001, HR = 4.692) were also found to be predictive
factors for poor prognosis of NPC patients (Table 3).
The parameters that were significant in univariate analy-
sis were further examined in multivariate analysis. After
multivariate adjustment, high SPARC expression
remained a powerful unfavorable predictor (P <0 . 0 0 1 ,
HR = 1.741) independent of other clinicopathological
factors, including age (P < 0.001, HR = 1.551) and clini-
cal stage (P < 0.001, HR = 4.766) (Table 3).
Discussion
NPC is a malignant neoplasm arising from the mucosal
epithelium of the nasopharynx, most often within the lat-
eral nasopharyngeal recess, and is thought to be closely
associated with Epstein-Barr virus infection, dietary, and
genetic factors. The majority of NPC-related deaths are
attributed to tumor metastasis rather than to the primary
tumor. However, the molecular mechanisms underlying
NPC invasion and metastasis are not completely under-
stood. Thus, novel molecular markers that can identify
tumor metastasis and aid in prognosis assessment are
urgently needed.
Immunohistochemistry is an indispensable research
tool frequently used to study tumor progression and
prognosis. Here, we evaluated SPARC protein expression
detected by immunohistochemical techniques in a large
and well-documented cohort of primary NPC samples,
and correlated the results with clinicopathological char-
acteristics and patient survival. In many NPC specimens,
over expression of SPARC was frequently detected. We
also demonstrated that SPARC was highly expressed at
both the mRNA and protein levels in NPC cell lines as
compared with NPEC2 Bmi-1. The expression of SPARC
in all normal nasopharyngeal epithelium detected by IHC
was absent, suggesting that SPARC is a common feature
in NPC that might play an important role in its prognosis
and metastasis.
Over-expression of SPARC was frequently observed in
the tumor specimens analyzed, and showed statistically
Figure 1 Expression of SPARC in cell lines. (A) Quantitative RT-PCR detection showed that NPC cell lines of CNE1, CNE2, HONE1, SUNE1 and
C666 presented higher level of mRNA expression of SPARC than that in NPEC2 Bmi-1. (B) Western blot analysis showed that the expression of
SPARC protein levels in NPC cell lines was higher than that in NPEC2 Bmi-1. (C) Quantitative RT-PCR detection showed that 5-8 F presented
higher level of mRNA expression of SPARC than that in 6-10B (P = 0.002). (D) Western blot analysis showed that the expression of SPARC protein
levels in 5-8 F was higher than that in 6-10B (P = 0.001). Results are shown as expression relative to GAPDH and are means (± SD) of 3
experiments.
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poor prognosis. In the patients here, higher SPARC
expression was significantly associated with tumor pro-
gression (metastasis and poor prognosis) and the
advanced stages of NPC. In addition, patients with lower
SPARC expression had an improved prognosis. These
observations between SPARC expression and tumor pro-
gression are consistent with other malignancies, such as
gastric cancer [13] and renal carcinoma [35]. The expres-
sion of SPARC has been positively correlated with the
histological grade of tumor cells in bladder cancer [21],
thyroid cancer [36], glioma [37] and HCC [38]. In the
present study, SPARC expression still remained a signifi-
cant predictor in the advanced stage. Radiotherapy has
become the standard treatment for NPC patients with
earlier stage. Although chemo-radiotherapy is a popular
therapy for advanced NPC, improving the survival of
these patients still remains a significant challenge [39].
SPARC may be a marker for advanced NPC as a potential
therapy agent. Advanced NPC patients with low SPARC
expression may accept the mild treatment without the
radical therapy. By contrast, advanced NPC patients with
higher SPARC expression may benefit from higher-dose
radiation, adjuvant therapy, or molecular target therapy.
Multivariate Cox proportional hazards survival analysis
suggested that SPARC over-expression had a significantly
worse prognostic impact (P < 0.001) on survival of NPC
patients. Consistent with the findings reported by the
previous studies, we confirmed that the independently
significant negative predictive factors for survival
included advanced increased age (P < 0.001) and
advanced clinical stage (P < 0.001) [40-42]. These results
indicate that as an independent risk factor, SPARC may
serve as a prognostic marker for survival of NPC patients.
Figure 2 Representative staining of SPARC in NPC tissue by immunohistochemistry. A (100×) and B (400 ×) showing the expression of
SPARC detection by IHC in NPC tumors and nasopharyngeal epithelium.; (C) no staining of SPARC in NPC tissue by immunohistochemistry; (D)
weak staining in cytoplasm; (E) moderate staining in cytoplasm; (F) strong staining in cytoplasm; (G), (H), (I), (J) showing the higher magnification
(200×) from the area of the box in (C), (D), (E) and (F), respectively.
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tion, and is generally recognized to mediate de-adhesion
thereby promote cell migration [43]. It has a profound
influence on cancer progression [44]. However, a pre-
vious study [45] revealed that SPARC expression was
higher in NPEC than in NPC cell lines. With the results
of the current study, we speculated that endogenous
SPARC expression was higher in NPC cell lines than in
the NPEC2 Bmi-1. This seems to contradict our current
study. One possible reason is that the current results
here were showed in a large retrospective cohort.
Another reason may be the difference in the distribution
of NPC patients and NPC cell types. Especially, high
levels of SPARC often correlated with the lymph node
metastasis, enhanced invasion, metastasis, and poor
prognosis [13,17,46,47], for example, metastasis to the
colon, lung, esophagus and pancreas [48]. Previous stu-
dies [49-51] using prostate cancer tissue samples
reported that SPARC expression was higher in meta-
static sites than in the primary site. These phenomena
Figure 3 Kaplan-Meier survival curve and log-rank test for NPC patients classified as showing either high or low SPARC expression. (A)
Kaplan-Meier curve for 5-year overall survival rate (69.1%) of 1093 patients with NPC; (B) Overall survival curve of NPC patients with different
SPARC expression and the 5-year OS rate was significantly different between NPC patients with low expression (74.9%) and high expression
(58.9%) (P < 0.001; log-rank test); (C) Cases stratified by clinical stage. Within the early stage (Stage I + II) stratum, SPARC expression did not show
a statistical (P = 0.256; log-rank test) relationship with patients survival; (D) Within the advanced stage (Stage III + IV) stratum, SPARC expression
exhibited a significant (P < 0.001; log-rank test) relationship with patients survival.
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gression in different tumor cell types and acts via differ-
ent signal transduction pathways [52].
Our study may have suffered from the limitation: as
discussed above the difference of SPARC expression
between the NPEC2 Bmi-1 cell line and NPEC was not
objectively verified. However, we chosen the NPEC2
Bmi-1 cell line as a control because it is the immorta-
lized cell line closest to normal nasopharyngeal epithe-
lium. Furthermore, the immortal NPEC cell line
(NPEC2 Bmi-1) is a pre-malignant nasopharyngeal
epithelial cell model and maintains a normal P53 check-
point [53]. Compared with nasopharyngeal carcinoma
cell lines, NPEC2 Bmi-1 cell line as a control may be
feasible.
While a High SPARC level indicates poorer prognosis
in some tumors, SPARC expression in neuroblastoma
inhibits angiogenesis and impairs tumor growth [54].
For example, the increased SPARC expression in pros-
tate cancer, bladder cancer [21], melanoma [24] and
Table 2 Associations between SPARC expression and clinicopathologic characteristics among all NPC cases
SPARC expression
Characteristics Low
(n = 701) (%)
High
(n = 392) (%)
r P-value
Age* (years)
≤ 47 366 (52.5) 202 (52.1)
> 47 331 (47.5) 186 (47.9) 0.004 0.887
Sex
Female 209 (29.8) 109 (27.8)
Male 492 (70.2) 283 (72.2) 0.021 0.483
Clinical stage
I + II 215 (30.8) 100 (25.6)
III + IV 482 (69.2) 291 (74.4) 0.056 0.066
Relapse
No 649 (92.7) 352 (89.8)
Yes 51 (7.3) 40 (10.2) 0.051 0.094
Metastasis
No 647 (92.4) 337 (86.0)
Yes 53 (7.6) 55 (14.0) 0.104 0.001
WHO histological classification
NKUC 566 (80.9) 287 (73.8)
NKDC 118 (16.9) 88 (22.6)
KSCC 16 (2.2) 14 (3.6) 0.082 0.023
*Median age; SPARC secreted protein acidic and rich in cysteine; NPC nasopharyngeal carcinoma; WHO World Health Organization; NKUC nonkeratinized
undifferentiated carcinoma; NKDC nonkeratinized differentiated carcinoma; KSCC keratinized squamous cell carcinoma
Table 3 Cox Regression analysis of the SPARC expression, clinicopathological variables for overall survival in NPC
patients
Variable Univariate Crude HR (95% CI) P value *Multivariate adjusted HR (95% CI) P value
SPARC expression
High versus Low 1.785 (1.455-2.190) < 0.001 1.741 (1.414-2.144) < 0.001
Agec (years)
>4 7versus ≤ 47 1.554 (1.265-1.910) < 0.001 1.551 (1.259-1.910) < 0.001
Sex
Female versus Male 0.780 (0.616-0.987) 0.039 0.854 (0.673-1.083) 0.193
Clinical Stage
III + IV versus I + II 4.692 (3.325-6.620) < 0.001 4.766 (3.361-6.758) < 0.001
WHO histological classification
NKDC versus NKUC 0.935 (0.716-1.222) 0.625 0.919 (0.701-1.205) 0.54
KSCC versus NKUC 1.988 (1.183-3.342) 0.01 1.804 (1.069-3.047) 0.027
*Adjusted for SPARC expression, sex, WHO histological classification, age, and clinical stage. SPARC secreted protein acidic and rich in cysteine; WHO World health
organization; NPC nasopharyngeal carcinoma; NKUC, non-keratinizing undifferentiated carcinoma; NKDC non-keratinizing differentiated carcinoma; KSCC
keratinizing squamous cell carcinoma; HR hazard ratio; CI confidence interval
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nancy and invasion of tumors with poor prognosis. In
contrast, in ovarian cancer, elevated SPARC expression
inhibited the invasion and metastasis of tumor cells
[30]. Thus, the varying influence of SPARC in different
tumors reflects that the function of SPARC may be tis-
sue-specific.
Conclusions
In summary, SPARC plays a crucial role in the process
of tumor invasion and metastasis in certain malignan-
cies. Regardless of the underlying biological mechanism,
SPARC expression status was proved to be of powerful
prognostic predictive value in distinguishing patients
w i t ham o r eb i o l o g i c a l l ya g g r e s s i v ea n di n v a s i v en a s o -
pharyngeal carcinoma. The data provided by our study
indicates that SPARC can serve as a useful biomarker to
better determine NPC prognosis and appropriate thera-
peutic model. Further clinical and experimental studies
are needed to define the genetic and/or epigenetic
mechanisms leading to SPARC over-expression, and to
better understand the role of SPARC in normal naso-
pharyngeal epithelium and NPC.
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